Pharmaron Beijing IPO Initiation: Clinically Sound
Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...
531 Views
HK IPO Analytics 1H2019: MS and CICC Stand Out
At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
600 Views
Last Week in GER Research: Budweiser, CIMC, Jinxin Fertility, 360 Finance, Zhongliang, and AMTD
Below is a recap of the key IPO and placement research produced by the Global Equity Research team. This week we update on the IPO valuation for...
463 Views
Frontage Holdings IPO: Bull/Bear Case DCF Scenarios
Frontage Holdings (1521 HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347 CH)....
633 Views
Frontage Holdings (方达控股) IPO: Reasonable Valuation & Quality Cornerstones
Frontage Holdings, a pre-clinical CRO arm of A-share listed Hangzhou Tigermed Consulting (300347 CH), started book building today to raise up to...
793 Views